Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHD
NCT05722912 · Status: APPROVED_FOR_MARKETING · Type: EXPANDED_ACCESS
Last updated 2023-02-10
Summary
To provide ruxolitinib through an expanded access to treat a single patient with cGVHD
Conditions
- Graft-versus-host Disease (GVHD)
Interventions
- DRUG
-
Ruxolitinib Cream
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Pooja Khandelwal, MD · Children's Hospital Medical Center, Cincinnati
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease After Failure of Systemic Glucocorticoids
NCT03616184 ·Status: COMPLETED ·Phase: PHASE2
-
Ruxolitinib Cream in Participants With Facial and/or Neck Atopic Dermatitis Involvement
NCT05127421 ·Status: COMPLETED ·Phase: PHASE2
-
Itacitinib for Low Risk GVHD
NCT03846479 ·Status: COMPLETED ·Phase: PHASE2
-
Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment
NCT04414514 ·Status: TERMINATED ·Phase: PHASE2
-
Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa
NCT05635838 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
NCT07049575 ·Status: RECRUITING ·Phase: PHASE1
-
Gene Therapy for Chronic Granulomatous Disease
NCT00394316 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute GVHD
NCT02614612 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)
NCT05764161 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Gecacitinib in the Treatment of Acute Graft-Versus-Host Disease After Failure of Ruxolitinib-containing Second-line Therapy
NCT07197112 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)
NCT05755438 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Itacitinib for the Treatment of Chronic Graft Versus Host Disease (cGVHD)
NCT04200365 ·Status: TERMINATED ·Phase: PHASE2
-
Ruxolitinib In GvHD
NCT02396628 ·Status: TERMINATED ·Phase: PHASE2
-
Managed Access Programs for INC424, Ruxolitinib
NCT04745637 ·Status: AVAILABLE
-
Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo
NCT04530344 ·Status: COMPLETED ·Phase: PHASE3
-
Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD
NCT06233110 ·Status: RECRUITING ·Phase: PHASE1
-
A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream
NCT06213831 ·Status: COMPLETED ·Phase: PHASE1
-
Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 Infection
NCT04355793 ·Status: NO_LONGER_AVAILABLE
-
Itacitinib (INCB039110) and Extracorporeal Photopheresis (ECP) for First-Line Treatment in Chronic GVHD
NCT04446182 ·Status: TERMINATED ·Phase: PHASE2
-
Itacitinib and Tocilizumab for Steroid Refractory Acute Graft Versus Host Disease
NCT04070781 ·Status: TERMINATED ·Phase: PHASE1
-
Topical Ruxolitinib Evaluation in Chronic Hand Eczema
NCT05906628 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease
NCT06388564 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)
NCT06959225 ·Status: RECRUITING ·Phase: PHASE3
-
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)
NCT02953678 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
NCT06548360 ·Status: RECRUITING ·Phase: PHASE3